Net Loss Per Share (Tables)

9 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table presents the computation of basic and diluted net loss per share for the three and nine months ended June 30, 2024 and 2023.

	Three Months Ended June 30,				Nine Months Ended June 30,
	2024		2023		2024		2023
	(in thousands, except per share amounts)
Numerator:
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	$	(170,793)	$	(102,946)	$	(428,957)	$	(95,596)
Denominator:
Weighted-average basic shares outstanding	124,199		107,004		118,260		106,597
Effect of dilutive securities	—		—		—		—
Weighted-average diluted shares outstanding	124,199		107,004		118,260		106,597
Basic net loss per share	$	(1.38)	$	(0.96)	$	(3.63)	$	(0.90)
Diluted net loss per share	$	(1.38)	$	(0.96)	$	(3.63)	$	(0.90)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.

	Three Months Ended June 30,		Nine Months Ended June 30,
	2024	2023	2024	2023
	(in thousands)
Options	753	637	711	768
Restricted stock units	3,976	2,830	4,060	3,256
Total	4,729	3,467	4,771	4,024